These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 12202955)

  • 41. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
    Uchiyama S; Yamaguchi M
    Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative analysis of osteoclast-specific gene markers stimulated by lipopolysaccharide.
    Jiang J; Li H; Fahid FS; Filbert E; Safavi KE; Spangberg LS; Zhu Q
    J Endod; 2006 Aug; 32(8):742-6. PubMed ID: 16861073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.
    Quinn JM; Elliott J; Gillespie MT; Martin TJ
    Endocrinology; 1998 Oct; 139(10):4424-7. PubMed ID: 9751528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
    Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
    J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts.
    Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K
    Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts.
    Boabaid F; Berry JE; Koh AJ; Somerman MJ; McCcauley LK
    J Periodontol; 2004 Sep; 75(9):1247-54. PubMed ID: 15515341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
    Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcium hydroxide reduces lipopolysaccharide-stimulated osteoclast formation.
    Jiang J; Zuo J; Chen SH; Holliday LS
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Mar; 95(3):348-54. PubMed ID: 12627109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences in the fusion and resorption activity of human osteoclasts after stimulation with different growth factors released from a polylactide carrier.
    Wildemann B; Kadow-Romacker A; Lübberstedt M; Raschke M; Haas NP; Schmidmaier G
    Calcif Tissue Int; 2005 Jan; 76(1):50-5. PubMed ID: 15477999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
    Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
    J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of beta-cryptoxanthin and zinc has potent effects on apoptotic cell death and suppression of bone resorption-related gene expression in osteoclastic cells.
    Yamaguchi M; Uchiyama S
    Int J Mol Med; 2008 Aug; 22(2):221-8. PubMed ID: 18636177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation.
    Shi Z; Silveira A; Patel P; Feng X
    Gene; 2004 Dec; 343(1):117-26. PubMed ID: 15563837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro.
    Xiao XH; Liao EY; Zhou HD; Dai RC; Yuan LQ; Wu XP
    J Endocrinol Invest; 2005 Mar; 28(3):253-60. PubMed ID: 15952411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.
    Tomita M; Li X; Okada Y; Woodiel FN; Young RN; Pilbeam CC; Raisz LG
    Bone; 2002 Jan; 30(1):159-63. PubMed ID: 11792579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.